Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Grants ROS1/NTRK Inhibitor Rights to AnHeart
December 19, 2018
- Shionogi Earns CHMP OK for Naldemedine
December 19, 2018
- Novo Links with H2 Inc. for Diabetes Treatment App
December 19, 2018
- Takeda, Alphabet's Health Unit Team Up on Japanese Parkinson’s Patient Research
December 19, 2018
- Adcetris Label Expansion Gets European Panel Nod: Takeda
December 18, 2018
- Hisamitsu Files Asenapine Transdermal Patch for Schizophrenia in US
December 18, 2018
- Eisai Grants to Eurofarma Exclusive Rights for Obesity Agent Lorcaserin in Brazil
December 18, 2018
- Efficacy of Fentos Tape for Cancer Pain in Opioid-Naïve Patients Confirmed in PIII Study: Hisamitsu
December 17, 2018
- Janssen Applies for Darzalex for Previously Untreated Multiple Myeloma Patients
December 17, 2018
- Gilead Files HIV Triplet Biktarvy in Japan, JT Pact Termination Set for Jan. 1
December 17, 2018
- Astellas Makes Full Inroads into I/O Arena with Potenza Buyout
December 17, 2018
- Lundbeck Japan to Quadruple Workforce by Next Summer, Eyes Vortioxetine Launch: Chief
December 14, 2018
- Astellas CEO Sees Cell Therapy Biz Model Established by “around 2030”
December 14, 2018
- ASKA to Review 5-Year Biz Plan after Hit by NHI Price Cut, Despite New Drug Launches
December 14, 2018
- Daiichi Sankyo Mulling Moving Up DS-8201 Filing to FY2019: Oncology Chief
December 13, 2018
- Ethical Drug Sales Up 2.0% in October: Crecon
December 13, 2018
- Otsuka’s US Subsidiary Pulls Plug on License Deal to Sumatriptan Nasal Spray for Acute Migraine
December 13, 2018
- Eisai, Takeda to Provide Compound Libraries to GARDP for Development of New Antibiotics
December 13, 2018
- Armed with 2 New Drugs, EA Pharma Looks to Raise Profile in Chronic Constipation Space
December 12, 2018
- Astellas FLT3 Inhibitor Xospata Now Available in US
December 12, 2018
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…